The respiratory depression of concomitant infusion of remimazolam and remifentanil using targeting effect-site concentrations

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0009178

Enrollment

108

Registered

2024-02-16

Start date

2024-05-30

Completion date

Unknown

Last updated

2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : While administering remimazolam with a target effect-site concentration maintaining a blood concentration of 500 ng/ml, the study aims to concurrently administer the narcotic analgesic remifent

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients aged 20-70 with American Society of Anesthesiologists (ASA) physical status classification of 2 or below, undergoing general anesthesia for scheduled gynecological surger

Exclusion criteria

Exclusion criteria: Patients with a BMI of 30 or higher, predicted difficult airway with Mallampatti class 3 or 4, presence of sleep apnea, history of lung disease, recent upper respiratory infection within the last 3 weeks, liver disorder (AST or ALT = 100 U/L), and renal impairment (serum creatinine = 2 mg/dL)

Design outcomes

Primary

Measure	Time frame
The frequency of loss of consciousness	—

Secondary

Measure	Time frame
The frequency of jaw thrust;The frequency of adminitrating 100% oxygen;The frequency of assist ventilation;tidal volulme;minute ventilation;time for loss of consciousness	—

Countries

Korea, Republic of

Contacts

Public ContactSoo Jung Park

Yonsei University Health System, Severance Hospital

crystal@yuhs.ac+82-2-2227-0574

Outcome results